Advertisement

Cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies: a case report

  • Silvia Maria VillaEmail author
  • Alessandra Rufa
  • Alessandro Malandrini
  • Alfonso Cerase
  • Francesca Rosini
  • Umberto Arrigucci
  • Antonio Federico
Letter to the Editor
  • 19 Downloads

Dear Editor,

Anti-glutamic acid decarboxylase (GAD) autoantibodies have been first described in patients with diabetes mellitus type 1 (DM1) and then found to be associated with several neurological syndromes including cerebellar ataxia [1]. These antibodies are usually directed against the 65 kDa isoform of the enzyme glutamic acid decarboxylase (GAD65), which produces gamma-aminobutyric acid (GABA) from glutamate in the nerve terminals. In the cerebellum, anti-GAD antibodies impair the GABA-synthesis in the cerebellar basket and stellate cells leading to a reduced inhibitory GABAergic postsynaptic transmission from Purkinje cells [2].

Case report

A 39-year-old man from Cameroon was referred to our attention in January 2017 for a 3-year history of difficulties in fine movement and coordination on the right hand and leg, followed by postural and gait instability, dizziness, and nausea. He had no medical history and denied use of drugs, alcohol, or particular diet habits. Family history...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

The authors declare that the study has been performed in accordance with ethical standards laid down in the 1964 Declaration of Helsinki.

References

  1. 1.
    Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, Ramió-Torrentà L, Graus F (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 131(Pt 10):2553–2563.  https://doi.org/10.1093/brain/awn183. CrossRefPubMedGoogle Scholar
  2. 2.
    Manto M, Mitoma H, Hampe CS (2018) Anti-GAD antibodies and the cerebellum: where do we stand? Cerebellum.  https://doi.org/10.1007/s12311-018-0986-6.
  3. 3.
    Jones AL, Flanagan EP, Pittock SJ, Mandrekar JN, Eggers SD, Ahlskog JE, McKeon A (2015) Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurol 72(11):1304–1312.  https://doi.org/10.1001/jamaneurol.2015.2378 CrossRefPubMedGoogle Scholar
  4. 4.
    Boronat A, Sabater L, Saiz A, Dalmau J, Graus F (2011) GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 76(9):795–800.  https://doi.org/10.1212/WNL.0b013e31820e7b8d CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Baizabal-Carvallo JF, Alonso-Juarez M (2017) Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review. J Neural Transm (Vienna) 124(10):1171–1182.  https://doi.org/10.1007/s00702-017-1754-3 CrossRefGoogle Scholar
  6. 6.
    Hosoi Y, Suzuki-Sakao M, Terada T, Konishi T, Ouchi Y, Miyajima H, Kono S (2013) GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies. J Neurol 260(12):3086–3092.  https://doi.org/10.1007/s00415-013-7092-y CrossRefPubMedGoogle Scholar

Copyright information

© Fondazione Società Italiana di Neurologia 2019

Authors and Affiliations

  1. 1.Department of Medicine, Surgery and Neurosciences, University of Siena. Unit of Neurology and Neurometabolic DisordersAzienda Ospedaliera Universitaria SeneseSienaItaly
  2. 2.Neuroimaging and Neurointervention Unit, Department of Neurological and Sensorineural SciencesAzienda Ospedaliera Universitaria SeneseSienaItaly

Personalised recommendations